tbuckley/cabot-search huggingface dataset:
Abstract 3115: Calcitriol effects on breast cancer tumorgrafts
Authors: Maria Lucia Hirata Katayama, Victor Celso N. Fonseca-Filho, Eduardo Carneiro Lyra, Durvanei Augusto Maria, Ricardo Alves Basso, Suely Nonogaki, Juliana Mariotti Guerra, Simone Maistro, João Carlos Sampaio Goes, Maria Aparecida A. Koike Folgueira
Journal: Cancer Research (2014)

Abstract Antiproliferative effects of calcitriol were mainly detected in breast carcinoma lineages exposed in vitro to high hormone concentrations, which is associated with hypercalcemia in human beings. To test the hypothesis that intra-tumoral administration of calcitriol would allow higher tissue concentration of the hormone and activation of the genomic pathway, a tumorgraft model, that more closely reproduces the molecular characteristics of the primary tumor, was established. Freshly collected breast cancer samples from 14 patients were ortothopically grafted in nude mice. On the sixth week after xenografting, no palpable nodules were detected in mice implanted with 6 samples. Intra-tumoral weekly injections of calcitriol 0.06 μg (dose that allow peak serum calcitriol levels in the predicted therapeutic range) or vehicle were initiated and maintained for six weeks in mice xenografted with another 8 samples. Tumorgraft proliferation, apoptosis and target genes expression were evaluated through immnunohistochemistry reactions or RT-PCR. At the end of the experiment, tumorgrafts originated from three samples were available for analysis. VDR expression was detected in these samples as well as a trend towards higher expression of CYP24A1 mRNA (10-18 fold) in calcitriol treated samples, indicating that the genomic pathway was induced. A high proliferative index, evaluated by Ki67 expression, was observed, however, neither differences in the expression of proliferation markers (BrdU incorporation, Ki67 and CDKN1B expression) nor in apoptosis markers (cleaved caspase 3 and BCL2 expression) between vehicle and calcitriol treated tumorgrafts was detected. Additionally, no difference between groups was noticed for the expression of CDKN1A mRNA. In summary, in this small study, calcitriol antitumoral effects were not observed in tumorgrafts, established from highly proliferative breast cancer samples. This preclinical model in conjunction with pharmacokinetic calcitriol determinations might contribute to clarify the hormone effects in breast cancer. Citation Format: Maria Lucia Hirata Katayama, Victor Celso N. Fonseca-Filho, Eduardo Carneiro Lyra, Durvanei Augusto Maria, Ricardo Alves Basso, Suely Nonogaki, Juliana Mariotti Guerra, Simone Maistro, João Carlos Sampaio Goes, Maria Aparecida A. Koike Folgueira. Calcitriol effects on breast cancer tumorgrafts. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3115. doi:10.1158/1538-7445.AM2014-3115
Hyperglycemia and Plasma Lipid Levels: Covariations in Insulin-dependent Diabetes
Authors: Jay M Sosenko, Jan Breslow, Olli S Miettinen, Kenneth H Gabbay
Journal: Diabetes Care (1982)

Longitudinal relationships of plasma lipids with parameters of blood glucose control were studied in 124 young insulin-dependent diabetic patients who had multiple, simultaneous determinations of these parameters during a 1-yr period. Fluctuations in hemoglobin A1, a cumulative measure of blood glucose control, correlated with fluctuations in total cholesterol (r = 0.19, P &amp;lt; 0.001) and low-density lipoprotein-cholesterol (r = 0.17, P &amp;lt; 0.001). Similarly, fluctuations in fasting blood glucose correlated with those in total cholesterol (r = 0.20, P &amp;lt; 0.001), very low-density lipoprotein-cholesterol (r = 0.13, P = 0.002), and total triglyceride (r = 0.23, P &amp;lt; 0.001). These data indicate covariation between plasma lipid and blood glucose control parameters and suggest that poor blood glucose control contributes to the excess risk of coronary heart disease in insulin-dependent diabetes mellitus.
Physostigmine Reversal of Cimetidine-lnduced Mental Confusion
Authors: Stanley R. Mogelnicki
Journal: JAMA (1979)

CIMETIDINE, a specific histamine H<sub>2</sub>receptor antagonist, is gaining a prominent role in the treatment of upper gastrointestinal bleeding and the prevention of stress ulceration in critically ill patients. Except for reversible depression of renal function, minimal adverse effects have been associated with its use. However, several recent reports linking mental confusion and cimetidine therapy have appeared.<sup>1,2</sup>Use of physostigmine salicylate to reverse this confusion has not been reported. The following is a description of two patients, critically ill after open heart surgery, who became increasingly obtunded during cimetidine therapy. After treatment with physostigmine or withdrawal of cimetidine, their alertness returned. <h3>Report of Cases</h3><h3>Case 1.—</h3> A 58-year-old, 60-kg man had an acute myocardial infarction, ruptured ventricular septum, congestive heart failure, and severe pulmonary edema. His other medical problems included prerenal azotemia, hepatomegaly, and history of peptic ulcer disease. After two weeks of intensive medical therapy, including intraaortic
Calculation of Survival of Patients With Stage III Melanoma
Authors: David Berd, Michael J. Mastrangelo, Takami Sato
Journal: Journal of Clinical Oncology (2005)

We are sending this letter almost 4 years after publication of the article, because we have become aware of a curious feature of the data that escaped our attention previously.The article analyzed the clinical outcomes of 17,600 melanoma patients in a database compiled from 13 cancer centers and cooperative groups around the world.The results of the analysis formed the basis of a new melanoma staging system that was adopted universally.What is unusual about the article is the method used for calculating the overall survival times of the patients with stage III melanoma.Whereas virtually all previously published studies used as the starting point the date of documentation of lymph node metastasis (usually the date of lymphadenectomy), Balch et al chose the date of diagnosis of the primary melanoma.The use of an earlier starting point may have affected the authors' conclusions, upon which the new staging system was based.The most important of those conclusions was the association of ulceration of the primary lesion with decreased overall survival in patients with stage III disease.At the time of the article's appearance, this was a striking and unexpected observation.However, it may be explained by the unorthodox method of survival analysis, because ulcerated primaries simply may have resulted in the more rapid development of nodal metastases.One wonders whether the prognostic importance
"Leg Syndrome" Following Rubella Vaccine
Authors: James Chin
Journal: JAMA (1973)

To the Editor.—  At least five published studies which Weibel et al did not cite have indicated that joint reactions to rubella vaccination do occur in children under 12 years of age. Although these were all retrospective studies, there is little doubt that these reactions do occur in young school children. Frequency and severity are greater for dog kidney vaccines as opposed to other types, yet 4% to 5% incidence in school children who received duck embryo vaccine has been demonstrated. Although these joint reactions are usually mild, a virtual absence of these complications should not be expected.  To the Editor.—  Drs. Kolansky and Moore (222:35, 1972) are to be commended for their careful clinical studies of the toxic effects of long-term cannabis use. One would hope that this type of clinical assessment of adverse effects would receive at least as much public attention as uninformed laymen's enthusiastic endorsements.  The
693. Regression of Established Subcutaneous B16 Melanoma Tumors after Intratumoral Delivery of a IL-15 Expressing Plasmid Followed by In Vivo Electroporation
Authors: Kenneth E. Ugen, Michelle Kutzler, Jeffrey Westover, Barbara Marerro, Chuanhai Cao, David B. Weiner, Richard Heller
Journal: Molecular Therapy (2005)

Melanoma is a major cancer due to metastasis; however, its initial cutaneous presentation makes it amenable to therapy. In vivo electroporation (E) has been used recently to efficaciously deliver conventional drugs and therapeutic genes to tumors, including melanomas. This study reports on the intratumoral (IT) delivery of DNA plasmids expressing interleukin-15 (IL-15), i.e. pIL-15, to established subcutaneous B16 melanoma tumors in C57BL6 mice. The IL-15 expression plasmid used was optimized for expression and was 80 fold more efficient than standard pcDNA3 based plasmids. IL-15 has been shown to have a pivotal role in the function of memory CD8 T cells and natural killer cells, both of which are critical for tumor immunosurveillance in vivo. In this study, female C57BL6 mice were injected, subcutaneously in the flank, with 1 million B16F10 melanoma cells. Approximately 7 days later, when tumor volumes were approximately 40 cu mm (day 0), mice (n=8/group) were randomized into different groups: untreated (V-P-E-) or treated with 50micrograms of pIL-15 (P) or backbone plasmid (V) with or without E (E+-/E-) (E conditions = 6 pulses 100microsecs 1500 V/cm). Subsequent treatments of the groups were made on days 4 and 7 and tumor volumes and survival among the groups were measured after the treatment regimen. Results at day 35-post treatment showed 0, 25 and 71% complete tumor regression in the V+-E+-, P+-E- and P+-E+- groups respectively. Likewise, at day 35 mice survival for the V+-E+-, P+-E-, P+-E+- and V-P-E- groups were 25, 50, 100 and 0% respectively. In addition, tumor growth, as measured by tumor volume, in mice without complete tumor regression was considerably less in the P+-E+- group (177 cu mm) when compared to the P+-E- (518 cu mm) and V+-E+-(1175 cu mm) groups. In addition, IL-15 expression in tumor lysates was considerably higher (7.5 fold) in the P+-E+- treated animals (21.6 pg/mg tumor) compared to the P+-E- group (2.9pg/mg tumor) demonstrating the efficacy of E+- to significantly enhance the expression of pIL-15 and potentially mediate an enhanced therapeutic effect. These results demonstrate the ability of an IL-15 expressing DNA plasmid to mediate an increase in complete regression of established subcutaneous B16 melanoma tumors when delivered intratumorally along with E. This is the first description of the ability of an IL-15 expressing DNA plasmid to alone mediate complete regression in this tumor type. These results are relevant since B16F10 tumors are characteristically difficult to treat and cure and underscores the potential clinical use of IL-15 for the treatment of malignant tumors when delivered with in vivo E. Mechanistic studies on the effects of the treatments reported here are being pursued and are centering on the previously established role of IL-15 in CD8+- T cell and natural killer cell activity.
High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression
Authors: J Boultwood, J Perry, R Zaman, C Fernandez-Santamaria, T Littlewood, R Kusec, A Pellagatti, L Wang, R E Clark, J S Wainscoat
Journal: Leukemia (2010)
Sinemet and the Treatment of Parkinsonism
Authors: BENJAMIN BOSHES
Journal: Annals of Internal Medicine (1981)

Sinemet (a combination of levodopa with carbidopa, a dopa-decarboxylase inhibitor) has replaced levodopa for early treatment of parkinsonism. The blocking of the systemic uptake of dopamine has eliminated the previous complications of nausea, vomiting, and cardiac and respiratory arrhythmias; pyridoxine need not now be avoided. However, the earlier appearance of abnormal involuntary movements, hallucinations, occasional psychosis, and a dopa-resistant state limits treatment efficacy. In all-over experience the combination drug offers the best relief for rigidity and akinesia. It has improved the quality of life and reduced mortality by one half. The greatest benefits appear in the first 3 years; then complications set in. The relation of complications to dosage is now better understood, and the ratio of dopadecarboxylase inhibitor to levodopa of 1:4 is better than the previous 1:10. Levodopa with or without dopa decarboxylase is not a cure for parkinsonism. Some agonist drugs (bromocryptine, lisuride) are showing promise in the testing stage. The evolving knowledge about neurotransmitters and peptide messengers offers hope for the growing number of patients with parkinsonism.
Plasma Exchange or Leukapheresis in the Hypereosinophilic Syndrome
Authors: JOHN DAVIES
Journal: Annals of Internal Medicine (1982)

Letters and Corrections1 June 1982Plasma Exchange or Leukapheresis in the Hypereosinophilic SyndromeJOHN DAVIES, CHRISTOPHER SPRYJOHN DAVIES, CHRISTOPHER SPRYAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-96-6-791_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: After reports of the successful treatment of the hypereosinophilic syndrome with leukapheresis (1, 2) we did plasma exchange, leukapheresis, or both on four patients with the hypereosinophilic syndrome. A comparison was made between the fall in eosinophil counts obtained by leukapheresis with those found after plasma exchange.We were surprised to find that on each occasion plasma exchange produced a larger percent fall in three patients (90%, 83%, and 35%) in the eosinophil count than did leukapheresis in the same three patients (38%, 27%, and 35%). Similar results were obtained after daily plasma exchanges on two other...References1. BLACKLOCKCLELANDTANPILLAI HJPV. The hypereosinophilic syndrome and leukapheresis [Letter]. Ann Intern Med. 1979;91:650-1. LinkGoogle Scholar2. ELLMANMILLERRAPPEPORT LLJ. Leukapheresis therapy of a hypereosinophilic disorder. JAMA. 1974;230:1004-5. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Royal Postgraduate Medical School London W12 OHS, England PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byWorld Health Organization‐defined eosinophilic disorders: 2021 update on diagnosis, risk stratification, and managementWorld Health Organization‐defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and managementWorld Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and managementComparison of two leukocytapheresis protocols in a case of idiopathic hypereosinophilic syndromeWorld Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and managementWorld Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and managementWorld Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and managementWorld Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and managementEosinophilic disorders: Molecular pathogenesis, new classification, and modern therapyThe FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and managementComplete Remission of Hypereosinophilic Syndrome after Interferon-α Therapy: Report of a Case and Literature ReviewAphresisHypereosinophilic Syndrome 1 June 1982Volume 96, Issue 6_Part_1Page: 791-791KeywordsBlood plasmaEosinophilsFalls Issue Published: 1 June 1982 PDF downloadLoading ...
Polydatin suppresses ultraviolet B-induced cyclooxygenase-2 expression<i>in vitro</i>and<i>in vivo</i>via reduced production of reactive oxygen species
Authors: Y.-D. He, Y.-T. Liu, Q.-X. Lin, J. Zhu, Y. Zhang, L.-Y. Wang, X.-L. Ren, X.-Y. Ye
Journal: British Journal of Dermatology (2012)

Funding sources: this work was supported by the grants from the Ministry of Science and Technology (2010CB945400). Conflicts of interest: none declared. Madam, Polydatin (resveratrol‐3‐O‐β‐d‐glucoside; Fig. 1a), a polyphenolic phytoalexin with a strong antioxidative activity, is isolated from the dried roots of Polygonum cuspidatum, which is widely used in traditional Chinese medicine.1, 2 In this study, we demonstrated the underlying mechanisms by which polydatin protects the skin from ultraviolet (UV) B‐induced damage in vitro and in vivo. Polydatin exerted no cell toxicity on HaCaT cells at low concentrations, as cell viability did not decrease when HaCaT cells were treated with various concentrations of polydatin up to 100 μg mL−1 (Fig. 1b). Irradiation with 30 mJ cm−2 of UVB resulted in 42·8 ± 2·7% of cell death compared with the nonirradiated group; polydatin reduced HaCaT cell death induced by UVB‐irradiation in a dose‐dependent manner (Fig. 1c). Furthermore, more cell death was observed after UVB irradiation compared with that seen in the nonirradiated groups. The effect of polydatin in reducing HaCaT cell death is shown in Figure 1d and Figure S1 (see Supporting information).
Identification of functional endothelial progenitor cells suitable for the treatment of ischemic tissue using human umbilical cord blood
Authors: Masumi Nagano, Toshiharu Yamashita, Hiromi Hamada, Kinuko Ohneda, Ken-ichi Kimura, Tomoki Nakagawa, Masabumi Shibuya, Hiroyuki Yoshikawa, Osamu Ohneda
Journal: Blood (2007)
Enhancing Induced Pluripotent Stem Cell Models of Schizophrenia
Authors: Rebecca Wright, János M. Réthelyi, Fred H. Gage
Journal: JAMA Psychiatry (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Budesonide and Nasal Histamine Challenge
Authors: Ulf Pipkorn
Journal: Allergy (1982)

The possible mode of action of the lately demonstrated steroid effect on the immediate type allergic reaction was investigated. The influence of a topical steroid, budesonide, on the effects that released mediators have on the nasal mucosa was also studied. A nasal histamine challenge study was performed in a double‐blind. cross‐over fashion, a 1‐weck. Pretreatment with budesonide or placebo preceding the challenge. Symptoms were recorded by means of symptom score as well as objectively via rhinomanometry. In contrast to a previous allergen challenge study, the steroid was found to have minimal effect on the histamine‐induced nasal symptoms. It is therefore concluded that other modes of steroid action must also be involved lin the steroid effect on the immediate type allergic reaction.
Prospective Associations of Concerns About Physique and the Development of Obesity, Binge Drinking, and Drug Use Among Adolescent Boys and Young Adult Men
Authors: Alison E. Field, Kendrin R. Sonneville, Ross D. Crosby, Sonja A. Swanson, Kamryn T. Eddy, Carlos A. Camargo, Nicholas J. Horton, Nadia Micali
Journal: JAMA Pediatrics (2013)

Relatively little is known about the prevalence of concerns with physique and eating disorders among males and their relation to subsequent adverse outcomes. A broader range of eating disorders needs to be defined to diagnose these illnesses appropriately in males.To investigate whether males with psychiatric symptoms related to disordered eating and concern about physique are more likely to become obese, to start using drugs, to consume alcohol frequently (binge drinking), or to develop high levels of depressive symptoms.The data come from questionnaires sent every 12 to 36 months from 1999 through 2010 to youth in a prospective cohort study, the Growing Up Today Study. The analysis included 5527 males aged 12 to 18 years in 1999 from across the United States who responded to the Growing Up Today Study questionnaires.Development of obesity and high levels of depressive symptoms and initiation of drug use and binge drinking at least monthly.From 1999 through 2011 in at least 1 study year, 9.2% of respondents reported high concerns with muscularity but no bulimic behaviors; 2.4%, high concerns with muscularity and use of supplements, growth hormone derivatives, or anabolic steroids to achieve their desired physique; 2.5%, high concerns with thinness but no bulimic behaviors; and 6.3%, high concerns with thinness and muscularity. For eating disorders, 0.8% had partial- or full-criteria bulimia nervosa or purging disorder and 2.9% had partial or full-criteria binge eating disorder but no association with the outcomes of interest. Infrequent binge eating or purging or overeating without a loss of control were reported by 31.0%. However, independent of age and body mass index, males with high concerns about thinness but not muscularity were more likely to develop high depressive symptoms (odds ratio, 2.72; 95% CI, 1.36-5.44). Males with high concerns about muscularity and thinness were more likely than their peers to use drugs (odds ratio, 2.13; 95% CI, 1.31-3.46), and males with high concerns about muscularity who used supplements and other products to enhance physique were more likely to start binge drinking frequently (2.06; 1.58-2.69) and using drugs (2.16; 1.49-3.11).High concerns with muscularity are relatively common among adolescent boys and young men. Males with these concerns who use potentially unhealthy products to improve their physique are at increased risk of adverse outcomes but may not be recognized by their health care providers as having a weight-related disorder because of the sex-specific presentation.